SEC Filings
Entera Bio Has $265.9 Million To Back Planned Late-Stage Osteoporosis Tablet Trial
Management expects funding to cover EB613 results and an FDA application, with operations supported into 2030.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Management expects funding to cover EB613 results and an FDA application, with operations supported into 2030.
Insider Trades
The co-CEO's reported holdings total 4,762,346 shares, held through trusts and family entities.
Earnings
The 2027–2028 framework keeps a 53% equity ratio and rules that split excess utility earnings with customers.
SEC Filings
PSE&G proposes delaying certain infrastructure costs until new rates take effect in 2028, keeping base distribution rates stable meanwhile.
Deals
The all-stock deal would combine more than 4.7 million water and wastewater connections under the American Water name.
SEC Filings
DTE Gas narrowed its quarterly loss, while Michigan regulators approved $149 million in additional annual revenue.
SEC Filings
The autoimmune-drug developer sold approximately $153.2 million under its previous offering and ended its unused capacity.
SEC Filings
The partnership expects approximately $2.68 billion before offering expenses to repay existing debt and fund general partnership purposes.
SEC Filings
Fox expects about $400 million in annual cost savings within two years while promising to preserve Roku’s open platform.
Deals
Roku’s board and executive officers exit their roles, and Nasdaq trading is set to halt before Monday’s opening.
Earnings
The managed-care company also maintains its standard-accounting earnings forecast at at least $2.38 per diluted share.
Insider Trades
The shares carry a stated aggregate market value of $11.2 million, with Fidelity Brokerage Services handling the proposed sale.